ABSTRACT

Background: Influenza is a common respiratory infection that may cause complications, including cardiovascular events. Influenza illness has been shown to double the risk of myocardial infarction, with the highest risk among patients with established cardiovascular disease. Vaccination against influenza has been associated with reductions in myocardial infarction, cerebrovascular disease, and death.

Objective: To evaluate the evidence for influenza vaccination as a strategy to reduce cardiovascular events specifically in patients with established cardiovascular disease.

Data Sources and Study Selection: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched with the terms "influenza vaccine" and "cardiovascular disease". Included in this review were randomized controlled trials (RCTs), nonrandomized studies, and meta-analyses that compared influenza vaccination against control in patients with established cardiovascular disease and that reported clinically meaningful cardiovascular outcomes (defined as cardiovascular death, myocardial infarction, and stroke).

Data Extraction and Synthesis: The search yielded 10 studies (3 nonrandomized studies, 5 RCTs, and 2 meta-analyses). The nonrandomized studies and the RCTs had inconsistent results with respect to cardiovascular death and adverse cardiovascular events. The 2 meta-analyses, which included the same 4 RCTs involving patients with established cardiovascular disease, showed that the influenza vaccine reduced cardiovascular death by about 50% relative to control. Vaccination also reduced major cardiovascular events by about 43%; the reduction was greater (54%) in the subgroup of patients with recent (≤ 1 year) acute coronary syndrome. However, these data are potentially confounded by small sample sizes, low event rates, and variable outcome reporting. There was also high clinical heterogeneity among the studies, which may not reflect contemporary practice.

Conclusions: Given the limitations of these data, it is unclear whether the cardiovascular benefit with influenza vaccination in patients with cardiovascular disease is a true effect. Nevertheless, because of the potential benefit and the low risk of adverse events, the annual influenza vaccine should be recommended for all patients with established cardiovascular disease.

Keywords: influenza, vaccination, cardiovascular disease, secondary prevention

RÉSUMÉ

Contexte : La grippe est une infection courante des voies respiratoires qui peut causer des complications, notamment des événements cardiovasculaires. On a montré que la grippe double les risques d’infarctus du myocarde. De plus, les patients atteints d’une maladie cardiovasculaire sont les plus menacés. La vaccination contre la grippe a été associée à une réduction des cas d’infarctus du myocarde, de maladie cérébrovasculaire et de décès.

Objectif : Évaluer les données probantes montrant que la vaccination contre la grippe permet de réduire le nombre d’événements cardiovasculaires chez les patients déjà atteints d’une maladie cardiovasculaire.

Sources des données et sélection des études : Les bases de données MEDLINE et Embase et le Registre central Cochrane des essais aléatoires ont été interrogés en utilisant les termes « vaccin antigrippal » et « maladie cardiovasculaire ». Les études retenues pour la présente revue de la littérature devaient être des essais cliniques à répartition aléatoire, des essais cliniques non aléatoires ou des méta-analyses. De plus, elles devaient comparer les résultats de patients vaccinés contre la grippe et atteints d’une maladie cardiaque à ceux d’un groupe témoin qui étaient aussi atteints d’une maladie cardiaque. Enfin, elles devaient signaler des résultats cardiovasculaires cliniquement significatifs (définis comme un décès d’origine cardiovasculaire, un infarctus du myocarde ou un accident vasculaire cérébral).

Extraction et synthèse des données : Dix études répondant aux critères de recherche (trois essais cliniques non aléatoires, cinq essais cliniques à répartition aléatoire et deux méta-analyses). Les essais cliniques non aléatoires et les essais cliniques à répartition aléatoire présentaient des résultats variables en ce qui touche aux décès d’origine cardiovasculaire et aux événements cardiovasculaires indésirables. Les deux méta-analyses, qui avaient en commun quatre essais cliniques à répartition aléatoire concernant des patients atteints d’une maladie cardiovasculaire, montraient que le vaccin contre la grippe permettrait de réduire le nombre de décès d’origine cardiovasculaire d’environ 50 % comparativement au groupe témoin. La vaccination a aussi réduit le nombre d’événements cardiovasculaires graves d’environ 43 % ; le pourcentage était plus important (54 %) dans le sous-groupe de patients ayant récemment (à l’intérieur d’un an) souffert d’un syndrome coronarien aigu. Cependant, ces résultats sont potentiellement biaisés par la petite taille des échantillons, les faibles taux d’événements et la variabilité avec laquelle on signale les résultats. Il y avait aussi une forte hétérogénéité clinique entre les études, ce qui pourrait ne pas être représentatif de la pratique actuelle.
INTRODUCTION

Influenza is a respiratory infection caused primarily by influenza A and B viruses. Influenza infection not only causes the primary respiratory illness, but also can lead to severe secondary medical complications, such as viral pneumonia, bacterial pneumonia, and worsening of underlying medical conditions, including cancer, diabetes mellitus, and renal disease. Influenza is ranked among the top 10 infectious diseases affecting Canadians, with about 10%–20% of the population becoming infected each year. On average, 12 200 hospital admissions and 3500 deaths related to influenza occur yearly in Canada. People at greatest risk of influenza-related complications are adults with underlying health conditions, including those with cardiac disorders. In Canada, influenza vaccination is recommended for all individuals aged 6 months and older who are considered at high risk, such as those with cardiovascular disease (CVD).

Multiple observational studies have assessed cardiovascular (CV) risk during the influenza season. Estimates from pooled data indicate that influenza infection, influenza-like illness, or respiratory tract infection doubles the risk of myocardial infarction (odds ratio [OR] 2.01, 95% confidence interval [CI] 1.47–2.76), and the highest risk is among those with established CVD. The mechanism by which influenza increases the risk of CV events is unclear, but may be related to triggering of rupture of vulnerable atherosclerotic plaques. Other contributing factors may involve impairment of the anti-inflammatory properties of high-density lipoprotein cholesterol through increased macrophage infiltration, or the sequelae of acute infection (e.g., fever, tachycardia, dehydration).

The influenza vaccine has been shown to reduce the risk of CV events, likely by reducing the risk of influenza infection. In observational trials, influenza vaccination has been associated with a decrease in the risk of myocardial infarction (OR 0.71, 95% CI 0.56–0.91), cerebrovascular disease (OR 0.77, 95% CI 0.66–0.89), and all-cause death (OR 0.50, 95% CI 0.46–0.55). However, in prospective randomized trials that included CV outcomes for safety assessment, influenza vaccination was not associated with a reduction in CV events, although these trials were limited by low event rates and potential for misclassification. Both the American Heart Association/American College of Cardiology and the European Society of Cardiology recommend the influenza vaccine annually for individuals with established CVD without specifically stating that the purpose is to reduce the risk of CV events. The objective of this systematic review was to evaluate the evidence for influenza vaccination as a strategy to reduce CV events in patients with established CVD.

METHODS

Data Sources

This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. The following databases were queried, using the search terms “influenza vaccine” and “cardiovascular disease”, from inception to February 2016: MEDLINE (including In-Process & Other Non-Indexed Citations), Embase, and the Cochrane Central Register of Controlled Trials. A medical librarian was consulted to aid in search strategy and article retrieval. The search was limited to human studies published in English. The reference lists of identified articles were manually searched to identify other relevant articles. One author (M.H.L.) performed the database search.

Study Selection

Included were matched nonrandomized studies (cohort and case–control studies), randomized controlled trials (RCTs), and meta-analyses of randomized or nonrandomized studies. Included studies must have investigated influenza vaccination versus placebo or no treatment in patients with established CVD and must have reported clinically meaningful CV outcomes (defined as CV death, myocardial infarction, or stroke).

Quality Assessment and Data Extraction

Both authors independently performed the study selection, data extraction, and quality assessment. The following data were extracted from each study: design, inclusion criteria, number of participants, baseline characteristics, intervention,
control, duration of follow-up, and CV outcomes (CV death and major adverse CV events [MACE], such as myocardial infarction or stroke). The quality of the included studies was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria. Any disagreement was resolved by discussion and consensus.

**RESULTS**

The database search yielded 452 citations, and 5 additional articles were identified from other sources (Figure 1). Forty-four studies were assessed in full by both authors, of which 34 citations were removed primarily because of a lack of CV outcome reporting. The remaining 10 articles (3 nonrandomized studies, 5 RCTs, and 2 meta-analyses) were included in the qualitative analysis.

**Nonrandomized Studies**

Details of the nonrandomized studies are presented in Table 1. All 3 studies were deemed to be of low or very low quality according to the GRADE criteria.

Grau and others performed a case–control study of 370 consecutive cases with admission for ischemic or hemorrhagic stroke or transient ischemic attack who were matched 1:1 on the basis of age, sex, and area of residence with 370 randomly selected controls. At baseline, control patients had a significantly higher rate of influenza vaccination during the last campaign than did case patients (31% versus 19%) and also a significantly higher rate of 1 or more influenza vaccinations within the past 5 years (44% versus 28%). Conversely, the case patients had higher rates of CV comorbidities than the controls, including hypertension (59% versus 41%), diabetes (22% versus 13%), hyperlipidemia (39% versus 31%), previous stroke (19% versus 6%), myocardial infarction (10% versus 7%), and current smoking (29% versus 19%). In the prespecified subgroup of patients with previous vascular disease, influenza vaccination was associated with a reduction in stroke or transient ischemic attack in an unadjusted analysis (OR 0.47, 95% CI 0.29–0.76); this result remained significant with adjustment for hypertension, alcohol abstinence, high alcohol consumption, and current sports participation (adjusted OR 0.45, 95% CI 0.26–0.76).

Heffelfinger and others performed a case–control study in a health maintenance organization in Seattle, Washington. Included were 750 cases (women or hypertensive men) aged 65–79 years with fatal or nonfatal myocardial infarction who were matched by sex, age category, calendar year, and presence of pharmacologically treated hypertension to 1735 controls from a stratified random sample. Cardiovascular disease was more common among the cases than the controls (31% versus 17%, p < 0.001), as were diabetes (23% versus 10%, p < 0.001) and current smoking (16% versus 10%, p < 0.001). In the subgroup of patients with pre-existing CVD, a multivariable analysis (adjusted for age, sex, history of treated hypertension, and index year) showed no association between influenza vaccination and incident myocardial infarction (adjusted OR 1.71, 95% CI 0.99–2.96).

**Table 1. Summary of Nonrandomized Trials**

<table>
<thead>
<tr>
<th>Study (Year)</th>
<th>GRADE Score</th>
<th>Design</th>
<th>No. of Patients</th>
<th>Baseline Characteristics</th>
<th>Exposed</th>
<th>Non-exposed</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grau et al. (2005)26</td>
<td>Very low</td>
<td>Matched case–control</td>
<td>740</td>
<td>Mean age 61 years, 69% male</td>
<td>Influenza vaccination</td>
<td>No influenza vaccination</td>
<td>18 months</td>
</tr>
<tr>
<td>Heffelfinger et al. (2006)27</td>
<td>Low</td>
<td>Matched case–control</td>
<td>2 485</td>
<td>Median age 73 years, 33% male</td>
<td>Influenza vaccination</td>
<td>No influenza vaccination</td>
<td>6 years</td>
</tr>
<tr>
<td>Lavallée et al. (2014)28</td>
<td>Low</td>
<td>Propensity score matched cohort</td>
<td>10 108</td>
<td>Mean age 70 years, 60% male</td>
<td>Influenza vaccination</td>
<td>Influenza vaccination</td>
<td>2 years</td>
</tr>
</tbody>
</table>

GRADE = Grading of Recommendations Assessment, Development and Evaluation.
Lavallée and others\textsuperscript{28} performed a propensity score-matched cohort study of 10,108 patients (50% vaccinated, 50% unvaccinated) with recent (8 days to < 6 months) ischemic stroke or transient ischemic attack using data from 3 prospective studies. For most of the patients (88%), stroke was the qualifying event. Statins were used by about 70% of patients, angiotensin-modulating agents by 65%, acetylsalicylic acid (ASA) by 60%, and \(\beta\)-blockers by 26%. The prespecified subgroup analysis of patients with a history of coronary artery disease \((n = 1784)\) did not show an association between influenza vaccination and MACE, which included cardiac death, nonfatal MI, and nonfatal stroke (hazard ratio [HR] 1.08, 95% CI 0.63–1.86), as well as fatal or nonfatal death, nonfatal MI, and nonfatal stroke (HR 0.95, 95% CI 0.51–1.78).

**Randomized Controlled Trials**

Details of the RCTs are presented in Table 2.\textsuperscript{29-34} Two of the RCTs were assessed to be of moderate quality and one was of low quality according to the GRADE criteria; quality assessment could not be performed for the remaining 2 RCTs, which have not been formally published in full-text.

The FLUVACS pilot study enrolled 301 patients with coronary artery disease who were randomly assigned to receive the seasonal influenza vaccine or placebo.\textsuperscript{29} More patients in the vaccination group than the placebo group presented with ST-segment elevation myocardial infarction (STEMI) (47% versus 37%), whereas fewer patients in the vaccination group presented with non-ST-segment elevation myocardial infarction (NSTE MI) (53% versus 63%). Among all of the patients with STEMI, 57% did not receive primary percutaneous coronary intervention (PCI) or fibrinolytic therapy, whereas 88% of the patients with NSTE MI received early conservative therapy. The use of \(\beta\)-blockers (64% of patients), angiotensin-converting enzyme (ACE) inhibitors (57%), and statins (34%) was relatively low. All of the patients received ASA. Overall, CV death was lower at 6 months among those who received influenza vaccination (2% versus 8%, relative risk [RR] 0.25, 95% CI 0.07–0.86), as was the composite of MACE, defined as CV death, nonfatal MI, or rehospitalization for ischemia.

### Table 2. Summary of Randomized Controlled Trials

<table>
<thead>
<tr>
<th>Study (Year)</th>
<th>GRADE Score</th>
<th>Design</th>
<th>Country</th>
<th>No. of Patients</th>
<th>Baseline Characteristics</th>
<th>Intervention</th>
<th>Control</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUVACS (2002 and 2004)\textsuperscript{31,32}</td>
<td>Low</td>
<td>Randomized, single-blind</td>
<td>Argentina</td>
<td>301</td>
<td>Mean age 65 years, 66% with acute MI, 34% with elective PCI</td>
<td>Single 0.5-mL IM dose of A/Moscow/10/99-like virus, A/New Caledonia/20/99 (H1N1)-like virus, and AB/Sichuan/379/99-like virus</td>
<td>Saline</td>
<td>6 months</td>
</tr>
<tr>
<td>FLUCAD (2008)\textsuperscript{31}</td>
<td>Moderate</td>
<td>Randomized, double-blind</td>
<td>Poland</td>
<td>658</td>
<td>Median age 60 years, 73% male, 56% with stable CAD, 24% with PCI for ACS, 20% with PCI for stable angina</td>
<td>Single 0.5-mL IM dose of A/New Caledonia/20/99 (H1N1), A/Christchurch/28/03 (H3N2), and B/Jiangsu/10/03</td>
<td>Placebo</td>
<td>14 months</td>
</tr>
<tr>
<td>Phrommintikul et al. (2011)\textsuperscript{32}</td>
<td>Moderate</td>
<td>Randomized, open-label</td>
<td>Thailand</td>
<td>439</td>
<td>Mean age 66 years, 57% male, 47% NSTE MI, 36% STEMI, 16% with unstable angina</td>
<td>Single 0.5-mL IM dose of split, inactivated influenza vaccine (type not reported)</td>
<td>No treatment</td>
<td>12 months</td>
</tr>
<tr>
<td>IVCAD (2009)\textsuperscript{33}</td>
<td>NA</td>
<td>Randomized, single-blind</td>
<td>Iran</td>
<td>281</td>
<td>NR</td>
<td>Single 0.5-mL IM dose of 2007/2008 influenza vaccine</td>
<td>Placebo</td>
<td>6 months</td>
</tr>
<tr>
<td>FLUVACS-IC*\textsuperscript{34}</td>
<td>NA</td>
<td>Randomized, single-blind</td>
<td>Argentina</td>
<td>117</td>
<td>NR</td>
<td>Single IM dose of influenza vaccine</td>
<td>Conventional medical therapy</td>
<td>6 months</td>
</tr>
</tbody>
</table>

ACS = acute coronary syndrome; CAD = coronary artery disease; GRADE = Grading of Recommendations Assessment, Development and Evaluation; IM = intramuscular; MI = myocardial infarction; NA = not applicable; NR = not reported; NSTE MI = non–ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

*Study was completed, but study results have not been published.
infectious Diseases in 2009. A total of 281 patients with the 19th European Congress of Clinical Microbiology and Adverse effects of the influenza vaccine; however, other treatment, and coronary revascularization, MACE remained significantly lower with vaccination (adjusted HR 0.67, 95% CI 0.51–0.86). There were no hospital admissions secondary to adverse effects of the influenza vaccine; however, other adverse events were not reported.

The IVCAD trial compared influenza vaccination with placebo in 658 patients with confirmed coronary artery disease. Patients had high utilization (>90%) of secondary CV preventive medications, including ASA, statins, ß-blockers, and ACE inhibitors, and about 50% were taking a thienopyridine. Influenza-like illness was reported more frequently in the unvaccinated group than in the vaccinated group (13% versus 8%, \( p = 0.042 \)). At 12 months, there was no difference in CV death (HR 1.06, 95% CI 0.15–7.56) or MACE, defined as CV death, acute MI, or coronary revascularization (HR 0.54, 95% CI 0.24–1.21). However, the composite of MACE or hospitalization for myocardial ischemia was lower with vaccination (HR 0.54, 95% CI 0.29–0.99). No severe adverse events were reported, and less than 5% of patients in both groups experienced minor, local, or generalized transient adverse effects.

Phommeintikul and others studied 439 patients admitted to hospital with acute coronary syndrome, who were randomly assigned to receive the influenza vaccine or no treatment. Of the patients who presented with STEMI, 43% received fibrinolytic therapy, 33% underwent primary PCI, and 23% received no reperfusion therapy. About 50% of patients who presented with NSTEMI had no revascularization. At baseline, 97% of the patients were taking ASA, 84% a statin, 74% a ß-blocker, and 59% an angiotensin-modulating agent. Influenza-like illness rates were not reported. The primary outcome of MACE (defined as death or hospitalization for acute coronary syndrome, heart failure, or stroke) was lower with vaccination than with no treatment (9.5% versus 19.3%, unadjusted HR 0.70, 95% CI 0.57–0.86), a result that was driven primarily by a reduction in hospitalization for acute coronary syndrome. Cardiovascular death was not significantly different between groups (HR 0.39, 95% CI 0.14–1.12). After adjustment for age, sex, serum creatinine, ACE inhibitor treatment, and coronary revascularization, MACE remained significantly lower with vaccination (adjusted HR 0.67, 95% CI 0.51–0.86). There were no hospital admissions secondary to adverse effects of the influenza vaccine; however, other adverse events were not reported.

The IVCAD trial was presented in abstract form at the 19th European Congress of Clinical Microbiology and Infectious Diseases in 2009. A total of 281 patients with coronary artery disease were randomly assigned to receive influenza vaccine or placebo. At 6 months, CV death was not significantly different between the groups. As well, the authors stated that none of the secondary outcomes (angina severity, coronary artery stenosis score, cardiac ejection fraction, or cardiac adverse events) were “markedly different” between groups. However, there was a significantly higher rate of at least one adverse cardiac event (acute coronary syndrome, coronary revascularization, or CV death) in the placebo group (rates not provided). Patients in the placebo group had a higher rate of influenza infection \( (p = 0.049) \), but no other adverse events were reported.

The FLUVACS-IC study was completed in March 2008. However, it has not been published, and information is available only through the Clinicaltrials.gov website (NCT00664339). In this study, 117 patients with New York Heart Association class III–IV heart failure requiring ventilator support (without endotracheal intubation) and high-dose loop diuretic therapy were randomly assigned to receive influenza vaccination or conventional therapy. At 6 months, CV death was reduced in the vaccination group (3% versus 17%, \( p = 0.022 \)), as was all-cause death or rehospitalization (33% versus 74%, \( p < 0.001 \)). No major adverse cardiac events were reported.

Meta-Analyses

A meta-analysis by Udell and others included 12 RCTs that compared influenza vaccination with placebo or standard of care, 4 of which included a total of 1655 patients with pre-existing CVD. The primary outcome was a composite of MACE (defined as CV death or hospitalization for myocardial infarction, unstable angina, stroke, heart failure, or urgent coronary revascularization). The mean age across these 4 RCTs was about 62 years, and roughly two-thirds were male. Follow-up ranged from 10 to 12 months. In the prespecified CVD subgroup, influenza vaccine significantly reduced both MACE (risk ratio 0.57, 95% CI 0.41–0.79, \( I^2 = 14\% \)) and CV death (risk ratio 0.50, 95% CI 0.27–0.95, \( I^2 = 15\% \)). In the prespecified subgroup of patients with recent (\( \leq 1 \) year) acute coronary syndrome (\( n = 815 \)), influenza vaccine significantly reduced MACE (risk ratio 0.46, 95% CI 0.33–0.64, \( I^2 = 0\% \)) but not CV death (risk ratio 0.44, 95% CI 0.17–1.15, \( I^2 = 38\% \)). There was no difference in MACE or CV death in the prespecified subgroup of patients with stable coronary artery disease (\( n = 840 \)).

A subsequent Cochrane Collaboration meta-analysis of 8 RCTS by Clar and others included the same 4 RCTs, but had a total of 1682 patients with CVD. Follow-up for these patients ranged from 10 to 12 months. As with the meta-analysis by Udell and others, CV death was significantly reduced with influenza vaccine (risk ratio 0.44, 95% CI 0.26–0.76, \( I^2 = 0\% \)). However, there was no difference in CV death.
in the subgroup of patients with acute coronary syndrome \( (n = 350) \) (risk ratio 0.46, 95% CI 0.04–5.20, \( I^2 = 58\% \)) or stable angina and elective PCI \( (n = 602) \) (risk ratio 0.35, 95% CI 0.07–1.73, \( I^2 = 0\% \)). The authors stated that they were unable to perform a meta-analysis for other CV events because of variable outcome reporting among the studies.

**DISCUSSION**

The highest level of evidence identified in this systematic review showed that, in patients with established CVD, influenza vaccine reduced CV death by a relative 50%–56%, a conclusion based on 2 meta-analyses that included the same 4 RCTs. Furthermore, influenza vaccination reduced MACE by a relative 43%, although this result was reported in only 1 of the 2 meta-analyses. A subgroup analysis demonstrated that the reduction in MACE was significant only among patients with recent acute coronary syndrome, not those with stable coronary artery disease. Despite including the same 4 RCTs, the total number of patients and the results of the 2 meta-analyses were similar but not identical. The relatively small sample sizes and event rates in the original studies, as well as variable outcome reporting, may explain the inconsistent results. The current systematic review highlights the lack of high-quality data investigating the effect of influenza vaccine in patients with CVD. It is acknowledged that the conclusions of this review rely almost entirely on the quality of the 2 meta-analyses because of the lack of additional RCTs identified and the limitations of the nonrandomized data.

It is difficult to reconcile the magnitude of the effect, given that the 2 highest-quality RCTs individually did not show a reduction in CV death.\(^{31,32}\) However, both of these RCTs enrolled a small number of patients, and thus may not have been sufficiently powered to detect a difference. Furthermore, small sample sizes may introduce confounding and bias, which may have resulted in overestimation of the true benefit for the RCTs with positive results. However, 2 independently performed meta-analyses calculated a similar relative risk reduction for CV death with minimal statistical heterogeneity \( (I^2 \leq 15\%) \) among patients with established CVD. Despite low statistical heterogeneity, there was marked clinical heterogeneity among the RCTs because of different study locations and practices, inclusion criteria, use of revascularization and secondary CV preventive medications, and composition of the influenza vaccine. It is challenging to assess publication bias because of the small number of trials included in each meta-analysis.\(^{37,38}\) The funnel plot in the meta-analysis by Udell and others\(^{28}\) suggested that small trials with CV benefit may remain unpublished; Clar and others\(^{36}\) did not assess publication bias in their meta-analysis.

In general, the identified RCTs were limited by small sample sizes, limited power, and imprecise effect estimates. Additionally, 2 of the 5 RCTs have not been formally published (and thus have not undergone peer review), and the limited information available on these studies (in the form of an abstract or trial registration) did not report many key aspects of study design and results. Furthermore, follow-up in most trials was limited to the influenza season (6 months on average), and there were no long-term data for patients receiving multiple influenza vaccinations over several years. Overall, adverse effects were not consistently reported; however, most were generally minor and transient. Other trials have reported a low incidence of adverse effects (0%–3%) and no significant difference in serious adverse events between influenza vaccine and placebo.\(^{35-37}\) Of the RCTs, FLUCAD\(^ {31}\) was likely the most well designed. The authors attempted to minimize bias and confounding through appropriate randomization, use of intention-to-treat analyses, and minimal loss to follow-up. As well, it was the only double-blind RCT identified in the literature search. This study was more reflective of modern practice than the others, as all patients who presented with acute coronary syndrome underwent PCI, and there was high utilization of secondary CV preventive medications. Although the results were neutral, the outcomes of CV death and MACE were likely underpowered—a post hoc sample-size calculation by the study’s authors showed that more than 2000 patients would have been needed to show statistical significance.

The nonrandomized trial data offer little value beyond the RCT data because of methodologic limitations and inconsistent results. In the highest-quality nonrandomized trial, conducted by Lavallée and others,\(^ {28}\) the influenza vaccine had a neutral effect on the subgroup of patients with coronary artery disease. Although propensity score matching was used to minimize differences between groups, and CV events were adjudicated in a blinded manner in 2 of the 3 studies that constituted the cohort in this study, exposure status was limited by potential misclassification bias due to patient self-reporting of vaccination status (which is subject to recall bias). Furthermore, the study was likely underpowered because of the small proportion of patients with a history of CVD. The 2 matched case–control studies\(^ {26,27}\) were homogeneous with regard to results: one showed a benefit with influenza vaccine, whereas the other was neutral. However, both of these studies were limited by differences in baseline characteristics that were not adjusted for in the analyses. As well, misclassification of cases may have occurred through patient self-reporting of vaccination status or errors in electronic health records.

Two RCTs assessing the effect of influenza vaccination on MACE in patients with heart failure (NCT01945268)\(^ {39}\) and established CVD (NCT00679237)\(^ {40}\) were in progress at the time of writing, with final data collection and study completion anticipated in December 2016 and December 2019, respectively.
Pharmacists in both community- and hospital-based practices are in an ideal position to provide influenza vaccination to patients, owing to their knowledge base and accessibility. Canadian legislation now permits pharmacists with proper certification to administer influenza vaccination to patients in 9 of the 10 provinces. Pharmacists should use this opportunity to identify patients with established CVD (particularly those with recent acute coronary syndrome) and to educate them about the reduction in CV death (53% relative risk reduction, 2.9% absolute risk reduction, number needed to treat 35) and CV events (43% relative risk reduction, 7.4% absolute risk reduction, number needed to treat 14) with the influenza vaccine over approximately one influenza season.

CONCLUSION

Influenza vaccination may be an effective strategy for reducing CV events in patients with pre-existing CVD.RCTs have had inconsistent results with respect to CV death and MACE because of small sample sizes, low event rates, and potential confounding and bias. However, meta-analyses of RCTs showed that the influenza vaccine reduced both CV death and MACE, relative to control, by about 50%. Given the limitations of the data, it is unclear whether this is a true effect. Nevertheless, because of the potential benefit and the low risk of adverse events, the annual influenza vaccine should be recommended for all patients with established CVD. Pharmacists can aid in identifying patients with established CVD who may benefit from the influenza vaccine, can educate patients about the potential CV benefits, and, with approved training, can provide the immunization.

References


---

**Marlys H LeBras,** BSP, PharmD, ACPR, was, at the time of writing, with the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia. She is now with the RxFiles Academic Detailing Program, Saskatoon Health Region, Saskatoon, Saskatchewan.

**Arden R Barry,** BSc, BSc(Pharm), PharmD, ACPR, is with the Chilliwack General Hospital, Lower Mainland Pharmacy Services, Chilliwack, British Columbia, and the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.

**Competing interests:** None declared.

**Address correspondence to:**
Dr Arden R Barry
Faculty of Pharmaceutical Sciences
The University of British Columbia
2405 Wesbrook Mall
Vancouver BC V6T 1Z3
e-mail: arden.barry@ubc.ca

**Funding:** None received.

**Acknowledgements:** The authors thank Marisa MacDonald, MLIS, Librarian, Chilliwack General Hospital, for her help with conducting the literature search.